Aminobisphosphonate-activated gammadelta T cells in immunotherapy of cancer: doubts no more.
- Authors: CACCAMO, NR; MERAVIGLIA, S; SCARPA, F; LA MENDOLA, C; SANTINI, D; BONANNO, CT; MISIANO, G; DIELI, F; SALERNO, A
- Publication year: 2008
- Type: Articolo in rivista (Articolo in rivista)
- Key words: Aminobisphosphonate, Gamma delta T cells, cancer
- OA Link: http://hdl.handle.net/10447/37793
Abstract
BACKGROUND: Activated V gamma 9 V delta 2 T cells are able to kill most tumour cells because of recognition by T cell receptor and natural killer receptors. OBJECTIVE: We discuss the possibility that the intentional activation of gammadelta T cells in vivo by aminobisphosphonates may represent a promising target for the design of novel and highly innovative immunotherapy in cancer patients. METHODS: The antitumoral effects of gammadelta T cells both in vitro and in vivo have been demonstrated suggesting a new therapeutic approach for translation into the clinical setting. RESULTS/CONCLUSION: V gamma 9 V delta 2 T lymphocytes represent a particularly interesting target for immunotherapeutic protocols based on N- aminobisphosphonate administration and several Phase I-II trials are ongoing investigating the activity of zoledronic acid plus IL-2 in solid tumours.